MedTrace Logo

Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

NCT00329693 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 182

Last updated 2011-05-19

No results posted yet for this study

Summary

Women included in this study are undergoing controlled ovarian hyperstimulation for assisted reproductive technologies (ART) and present with signs of moderate risk of developing OHSS.

Conditions

  • Ovarian Hyperstimulation Syndrome

Interventions

DRUG

Norprolac

Placebo

DRUG

Norprolac

Quinagolide

DRUG

Norprolac

Quinagolide

DRUG

Norprolac

Quinagolide

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-06-30
Primary Completion
2007-08-31
Completion
2008-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329693 on ClinicalTrials.gov